SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Fundamental Analysis & Valuation

FRA:1SXP • DE000A3ENQ51

Current stock price

12.96 EUR
-0.26 (-1.97%)
Last:

This 1SXP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. 1SXP.DE Profitability Analysis

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • 1SXP had a positive operating cash flow in the past year.
  • In the past 5 years 1SXP has always been profitable.
  • In the past 5 years 1SXP always reported a positive cash flow from operatings.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • 1SXP has a better Return On Assets (9.26%) than 89.47% of its industry peers.
  • The Return On Equity of 1SXP (16.21%) is better than 89.47% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 12.84%, 1SXP belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
  • 1SXP had an Average Return On Invested Capital over the past 3 years of 14.59%. This is significantly above the industry average of 9.20%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • 1SXP's Profit Margin of 15.13% is amongst the best of the industry. 1SXP outperforms 84.21% of its industry peers.
  • In the last couple of years the Profit Margin of 1SXP has grown nicely.
  • The Operating Margin of 1SXP (19.08%) is better than 73.68% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • 1SXP has a Gross Margin of 33.68%. This is comparable to the rest of the industry: 1SXP outperforms 42.11% of its industry peers.
  • In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. 1SXP.DE Health Analysis

2.1 Basic Checks

  • 1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for 1SXP remains at a similar level compared to 5 years ago.
  • Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • The Debt to FCF ratio of 1SXP is 7.05, which is on the high side as it means it would take 1SXP, 7.05 years of fcf income to pay off all of its debts.
  • 1SXP has a Debt to FCF ratio (7.05) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.08 indicates that 1SXP is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.08, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.41
WACC9.08%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.58. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP's Current ratio of 1.58 is fine compared to the rest of the industry. 1SXP outperforms 63.16% of its industry peers.
  • A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.17, 1SXP is doing good in the industry, outperforming 68.42% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 1SXP.DE Growth Analysis

3.1 Past

  • The earnings per share for 1SXP have decreased by -2.02% in the last year.
  • 1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.78% yearly.
  • The Revenue has been growing slightly by 4.39% in the past year.
  • The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.01% on average per year.
  • The Revenue is expected to grow by 5.75% on average over the next years.
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. 1SXP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.36, which indicates a correct valuation of 1SXP.
  • Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
  • 1SXP's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.23.
  • The Price/Forward Earnings ratio is 11.88, which indicates a very decent valuation of 1SXP.
  • Based on the Price/Forward Earnings ratio, 1SXP is valued cheaply inside the industry as 89.47% of the companies are valued more expensively.
  • 1SXP is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.28, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.36
Fwd PE 11.88
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a rather cheap valuation: 1SXP is cheaper than 89.47% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 68.42% of the companies in the same industry.
Industry RankSector Rank
P/FCF 164.34
EV/EBITDA 7.32
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • 1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.97
EPS Next 2Y6.04%
EPS Next 3Y8.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 1SXP.DE Dividend Analysis

5.1 Amount

  • 1SXP has a Yearly Dividend Yield of 1.36%.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.60. 1SXP pays more dividend than 94.74% of the companies in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.89, 1SXP is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.36%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 15.99% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP15.99%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

1SXP.DE Fundamentals: All Metrics, Ratios and Statistics

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (3/20/2026, 7:00:00 PM)

12.96

-0.26 (-1.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners20.95%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.95B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts76.84
Price Target19.93 (53.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.36%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.13%
PT rev (3m)-30.29%
EPS NQ rev (1m)-1.42%
EPS NQ rev (3m)-9.81%
EPS NY rev (1m)-4.55%
EPS NY rev (3m)-17.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.87%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-5.95%
Valuation
Industry RankSector Rank
PE 13.36
Fwd PE 11.88
P/S 1.96
P/FCF 164.34
P/OCF 12.28
P/B 2.1
P/tB 2.17
EV/EBITDA 7.32
EPS(TTM)0.97
EY7.48%
EPS(NY)1.09
Fwd EY8.42%
FCF(TTM)0.08
FCFY0.61%
OCF(TTM)1.06
OCFY8.14%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)N/A
PEG (5Y)0.97
Graham Number11.61
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC9.08%
ROIC/WACC1.41
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y-1.71%
EPS Next 2Y6.04%
EPS Next 3Y8.07%
EPS Next 5Y8.01%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.29%
Revenue Next 2Y4.62%
Revenue Next 3Y5.35%
Revenue Next 5Y5.75%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.81%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 5 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to decline by -1.71% in the next year.